Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (902)	2/5/2002 2:24:06 PM
From: scaram(o)uche	Respond to of 2243

Over and over again, the same thing.... the joint venture buys something that they probably don't need. The end result? Management at the small bio gets cash to run the company with, but their shareholders give up a lot of the potential upside. Each deal allows ELN to move in on a real chunk of future success, in the JV and/or the small partner. This company has been known as an accounting puff since 1997. Given Enron, what are the chances that this was an orchestrated attack, that someone is working to take a large chunk of what Elan had built? If deep pharma pockets would move in on this now, before real damage sets in (motivation of the sales force, etc.), it would be very wise IMO. A route to also buying a piece of Biogen's future, for those who covet it?